All In MedTech

Device Trial Radar · NCT07744984

The Efficacy of Home OCT Supported Management in Patients Diagnosed With Neovascular-AMD and Undergoing a Drug Switch to Faricimab

Home OCT-Guided Management of Neovascular Age Related Macular Degeneration: Outcomes and Insight After Switch to Faricimab for One Year

Last checked: Nov 19, 2026Latest source record: Sep 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

12

Actual

Start

Jul 3, 2024

Primary completion

Apr 1, 2026

Study completion Jul 1, 2026

Sponsor

Lead sponsor
Rabin Medical CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Aug 4, 2026

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Age-related macular degeneration (AMD) is a common eye disease that can lead to vision loss. The neovascular ("wet") form of AMD is usually treated with repeated injections into the eye. However, some patients do not respond well to their current treatment and need to switch to a different medication. The purpose of this study is to evaluate whether using a home optical coherence tomography (Home OCT) device can improve the management of patients with neovascular AMD who are switching to faricimab treatment after an insufficient response to previous therapy. The Home OCT device allows participants to perform retinal scans at home several times a week. These scans are securely transmitted to the study team, allowing physicians to monitor changes in the retina more frequently than with routine clinic visits alone. Participants will continue to receive the standard medical care determined by their treating retina specialist, including clinic visits, eye examinations, retinal imaging, and intravitreal injections. The Home OCT device will provide additional information to help detect changes in disease activity between clinic visits. If the scans suggest worsening of the condition, participants may be asked to return for an earlier evaluation. The study aims to determine whether frequent home monitoring can identify treatment response sooner and support more personalized treatment decisions. The study will also collect information on the effectiveness of faricimab in routine clinical practice after switching from previous anti-VEGF therapy.

Conditions

  • Age-Related Macular Degeneration (AMD)
  • Neovascular Age-Related Macular Degeneration (nAMD) Wet AMD

Interventions

  • Home Optical Coherence Tomography (Home OCT)Device

    Participants will be provided with a Notal Vision Home OCT device for home retinal imaging. They will perform self-imaging at least four times per week throughout the study. OCT images will be securely transmitted to the study team for remote review, enabling frequent monitoring of retinal fluid and disease activity in addition to routine clinical care

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Measure the efficacy of Home-OCT in the management of nvAMD treated with Faricimab.Time frame: Up to 12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Rabin Medical Center

    Petah Tikva, Israel, Israel

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.